Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients

Roser Velasco, Jordi Bruna, Chiara Briani, Andreas A. Argyriou, Guido Cavaletti, Paola Alberti, Barbara Frigeni, Mario Cacciavillani, Sara Lonardi, Diego Cortinovis, Marina Cazzaniga, Cristina Santos, Haralabos P. Kalofonos

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Objectives: Peripheral neuropathy ranks among the most common dose-limiting and disabling side-effect of oxaliplatin (OXA)-based chemotherapy. The aim of this prospective, multicentre study was to define early clinical and neurophysiological markers that may help to identify patients at risk of developing severe, treatment emergent, cumulative OXA-induced peripheral neuropathy (OXAIPN). Methods: 200 colorectal cancer patients, scheduled to receive OXA-based chemotherapy, were prospectively followed. Detailed neurological assessment employing the clinical Total Neuropathy Score (TNSc), oncological rating scales (National Common Institute-Common Toxicity Criteria V.3) and nerve conduction studies (NCS) were performed at baseline, mid-treatment and at the end of chemotherapy. Symptoms of OXA-induced acute neurotoxicity were systematically recorded. Results: According to TNSc, 36 (18%) patients developed grade 3 OXAIPN. These patients were predominantly men ( p=0.005), presented a significant decrease in all NCS (p30% decrease in sensory nerve action potential amplitude from the baseline value in radial (OR 41.4; CI 95% 4.98 to 343.1; p=0.001) and dorsal sural nerves (OR 24.96; CI 95% 2.6 to 239.4; p=0.005) were independently associated with the risk of developing severe OXAIPN. Conclusions: High-grade OXA neurotoxicity can be predicted by clinical and neurophysiological information obtained at mid-treatment. Neurological assessment of acute neuropathy symptoms and radial and dorsal sural nerves NCS should be carefully monitored to predict and hopefully prevent the induction of severe OXAIPN.

Original languageEnglish
Pages (from-to)392-398
Number of pages7
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume85
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

oxaliplatin
Peripheral Nervous System Diseases
Colorectal Neoplasms
Neural Conduction
Sural Nerve
Drug Therapy
Radial Neuropathy
Action Potentials
Multicenter Studies
Therapeutics
Biomarkers
Cancer Patients
Predictors
Nerve
Prospective Studies

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Surgery
  • Arts and Humanities (miscellaneous)

Cite this

Velasco, R., Bruna, J., Briani, C., Argyriou, A. A., Cavaletti, G., Alberti, P., ... Kalofonos, H. P. (2014). Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. Journal of Neurology, Neurosurgery and Psychiatry, 85(4), 392-398. https://doi.org/10.1136/jnnp-2013-305334

Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. / Velasco, Roser; Bruna, Jordi; Briani, Chiara; Argyriou, Andreas A.; Cavaletti, Guido; Alberti, Paola; Frigeni, Barbara; Cacciavillani, Mario; Lonardi, Sara; Cortinovis, Diego; Cazzaniga, Marina; Santos, Cristina; Kalofonos, Haralabos P.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 85, No. 4, 2014, p. 392-398.

Research output: Contribution to journalArticle

Velasco, R, Bruna, J, Briani, C, Argyriou, AA, Cavaletti, G, Alberti, P, Frigeni, B, Cacciavillani, M, Lonardi, S, Cortinovis, D, Cazzaniga, M, Santos, C & Kalofonos, HP 2014, 'Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients', Journal of Neurology, Neurosurgery and Psychiatry, vol. 85, no. 4, pp. 392-398. https://doi.org/10.1136/jnnp-2013-305334
Velasco, Roser ; Bruna, Jordi ; Briani, Chiara ; Argyriou, Andreas A. ; Cavaletti, Guido ; Alberti, Paola ; Frigeni, Barbara ; Cacciavillani, Mario ; Lonardi, Sara ; Cortinovis, Diego ; Cazzaniga, Marina ; Santos, Cristina ; Kalofonos, Haralabos P. / Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. In: Journal of Neurology, Neurosurgery and Psychiatry. 2014 ; Vol. 85, No. 4. pp. 392-398.
@article{0f593a051f304d56bfbb7ea0db0ab347,
title = "Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients",
abstract = "Objectives: Peripheral neuropathy ranks among the most common dose-limiting and disabling side-effect of oxaliplatin (OXA)-based chemotherapy. The aim of this prospective, multicentre study was to define early clinical and neurophysiological markers that may help to identify patients at risk of developing severe, treatment emergent, cumulative OXA-induced peripheral neuropathy (OXAIPN). Methods: 200 colorectal cancer patients, scheduled to receive OXA-based chemotherapy, were prospectively followed. Detailed neurological assessment employing the clinical Total Neuropathy Score (TNSc), oncological rating scales (National Common Institute-Common Toxicity Criteria V.3) and nerve conduction studies (NCS) were performed at baseline, mid-treatment and at the end of chemotherapy. Symptoms of OXA-induced acute neurotoxicity were systematically recorded. Results: According to TNSc, 36 (18{\%}) patients developed grade 3 OXAIPN. These patients were predominantly men ( p=0.005), presented a significant decrease in all NCS (p30{\%} decrease in sensory nerve action potential amplitude from the baseline value in radial (OR 41.4; CI 95{\%} 4.98 to 343.1; p=0.001) and dorsal sural nerves (OR 24.96; CI 95{\%} 2.6 to 239.4; p=0.005) were independently associated with the risk of developing severe OXAIPN. Conclusions: High-grade OXA neurotoxicity can be predicted by clinical and neurophysiological information obtained at mid-treatment. Neurological assessment of acute neuropathy symptoms and radial and dorsal sural nerves NCS should be carefully monitored to predict and hopefully prevent the induction of severe OXAIPN.",
author = "Roser Velasco and Jordi Bruna and Chiara Briani and Argyriou, {Andreas A.} and Guido Cavaletti and Paola Alberti and Barbara Frigeni and Mario Cacciavillani and Sara Lonardi and Diego Cortinovis and Marina Cazzaniga and Cristina Santos and Kalofonos, {Haralabos P.}",
year = "2014",
doi = "10.1136/jnnp-2013-305334",
language = "English",
volume = "85",
pages = "392--398",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients

AU - Velasco, Roser

AU - Bruna, Jordi

AU - Briani, Chiara

AU - Argyriou, Andreas A.

AU - Cavaletti, Guido

AU - Alberti, Paola

AU - Frigeni, Barbara

AU - Cacciavillani, Mario

AU - Lonardi, Sara

AU - Cortinovis, Diego

AU - Cazzaniga, Marina

AU - Santos, Cristina

AU - Kalofonos, Haralabos P.

PY - 2014

Y1 - 2014

N2 - Objectives: Peripheral neuropathy ranks among the most common dose-limiting and disabling side-effect of oxaliplatin (OXA)-based chemotherapy. The aim of this prospective, multicentre study was to define early clinical and neurophysiological markers that may help to identify patients at risk of developing severe, treatment emergent, cumulative OXA-induced peripheral neuropathy (OXAIPN). Methods: 200 colorectal cancer patients, scheduled to receive OXA-based chemotherapy, were prospectively followed. Detailed neurological assessment employing the clinical Total Neuropathy Score (TNSc), oncological rating scales (National Common Institute-Common Toxicity Criteria V.3) and nerve conduction studies (NCS) were performed at baseline, mid-treatment and at the end of chemotherapy. Symptoms of OXA-induced acute neurotoxicity were systematically recorded. Results: According to TNSc, 36 (18%) patients developed grade 3 OXAIPN. These patients were predominantly men ( p=0.005), presented a significant decrease in all NCS (p30% decrease in sensory nerve action potential amplitude from the baseline value in radial (OR 41.4; CI 95% 4.98 to 343.1; p=0.001) and dorsal sural nerves (OR 24.96; CI 95% 2.6 to 239.4; p=0.005) were independently associated with the risk of developing severe OXAIPN. Conclusions: High-grade OXA neurotoxicity can be predicted by clinical and neurophysiological information obtained at mid-treatment. Neurological assessment of acute neuropathy symptoms and radial and dorsal sural nerves NCS should be carefully monitored to predict and hopefully prevent the induction of severe OXAIPN.

AB - Objectives: Peripheral neuropathy ranks among the most common dose-limiting and disabling side-effect of oxaliplatin (OXA)-based chemotherapy. The aim of this prospective, multicentre study was to define early clinical and neurophysiological markers that may help to identify patients at risk of developing severe, treatment emergent, cumulative OXA-induced peripheral neuropathy (OXAIPN). Methods: 200 colorectal cancer patients, scheduled to receive OXA-based chemotherapy, were prospectively followed. Detailed neurological assessment employing the clinical Total Neuropathy Score (TNSc), oncological rating scales (National Common Institute-Common Toxicity Criteria V.3) and nerve conduction studies (NCS) were performed at baseline, mid-treatment and at the end of chemotherapy. Symptoms of OXA-induced acute neurotoxicity were systematically recorded. Results: According to TNSc, 36 (18%) patients developed grade 3 OXAIPN. These patients were predominantly men ( p=0.005), presented a significant decrease in all NCS (p30% decrease in sensory nerve action potential amplitude from the baseline value in radial (OR 41.4; CI 95% 4.98 to 343.1; p=0.001) and dorsal sural nerves (OR 24.96; CI 95% 2.6 to 239.4; p=0.005) were independently associated with the risk of developing severe OXAIPN. Conclusions: High-grade OXA neurotoxicity can be predicted by clinical and neurophysiological information obtained at mid-treatment. Neurological assessment of acute neuropathy symptoms and radial and dorsal sural nerves NCS should be carefully monitored to predict and hopefully prevent the induction of severe OXAIPN.

UR - http://www.scopus.com/inward/record.url?scp=84895820491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895820491&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2013-305334

DO - 10.1136/jnnp-2013-305334

M3 - Article

C2 - 23813745

AN - SCOPUS:84895820491

VL - 85

SP - 392

EP - 398

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 4

ER -